An automatic Google result: CytoDyn Inc. (CYD
Post# of 151654

CytoDyn Inc. (CYDY), a biotechnology company, is developing leronlimab, a CCR5 antagonist, and has announced encouraging survival outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with leronlimab, with some patients surviving more than 36 months after treatment.
Nice @ 1st time seeing that....
Come on May !!

